Af­ter decades in the big leagues, Mar­tin Mack­ay is go­ing small — and he's de­light­ed

Mar­tin Mack­ay has spent more than three decades in drug dis­cov­ery and de­vel­op­ment, reach­ing top R&D po­si­tions at Pfiz­er, As­traZeneca and Alex­ion, where he en­joyed big bud­gets in pur­suit of block­buster drugs and styl­ish­ly sur­vived a se­ries of big cor­po­rate shake­ups.

Stephen Uden

Now, the Scot­tish re­search ex­ec and some of his ex-Alex­ion col­leagues are go­ing small, in a big way. Mack­ay, for­mer Alex­ion SVP Stephen Uden and for­mer Alex­ion tax chief Jef­frey Fry­er band­ed to­geth­er af­ter the big Lud­wig Hantson purge in 2017 to start Rally­bio at the be­gin­ning of this year. And some mar­quee ven­ture groups are bankrolling their ef­fort with a $37 mil­lion A round.

“I just feel we have some meds left in us,” says Mack­ay. 

Jef­frey Fry­er

The cash will go to build­ing out a small team at Rally­bio, where Mack­ay and his co-founders have been scout­ing rare dis­ease drugs in acad­e­mia and phar­ma, plan­ning to start build­ing a pipeline of drugs with an eye to ex­e­cut­ing a quick piv­ot to reg­u­la­tors.

5AM Ven­tures, Canaan Part­ners, and New Leaf Ven­ture Part­ners led the fi­nanc­ing, with Con­necti­cut In­no­va­tions lend­ing some state sup­port for the Farm­ing­ton, CT-based com­pa­ny.

“It would be eas­i­er to say what we’re not go­ing to do,” Mack­ay tells me. He ticks off the don’t-go-there list: On­col­o­gy, in­fec­tious dis­eases, oph­thal­mol­o­gy and vac­cines. They’re stick­ing with what they know: an­ti­bod­ies, small mol­e­cules and en­gi­neered pro­teins.

There are no ge­o­graph­ic bound­aries to their search. Uden has worked a lengthy stint in Japan. They all have ex­ten­sive Eu­ro­pean ex­pe­ri­ence, Mack­ay’s old stomp­ing grounds be­fore in­vestors drove a purge at As­traZeneca that brought Pas­cal So­ri­ot to the helm. The US is home, but they’re not lim­it­ing them­selves to the big hubs in Boston/Cam­bridge and the Bay Area.

Right now, they have the mon­ey to get to work and some lines on some ear­ly-stage as­sets.

“We’d be look­ing for ear­ly proof-of-con­cept to piv­ot to a reg­u­la­to­ry OK,” says Mack­ay, who’s tak­ing the CEO post at the new com­pa­ny.

Now with a staff of about 8, Mack­ay plans to build a group of 15 sci­en­tists and one busi­ness per­son to keep an eye on the num­bers. He plans to keep it sim­ple — there’s no ad­min­is­tra­tive as­sis­tant to book trav­el — with a bare­bones bud­get.

Mack­ay knows what it’s like to man­age glob­al re­search groups. Now he wants to see just how nim­ble a lit­tle biotech can be.


Im­age: Mar­tin Mack­ay. NO­VO NORDISK

#ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.

The deal, announced last weekend, gives California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

When AstraZeneca trumpeted “momentous” and “transformative” results for Tagrisso earlier this year at ASCO, some practitioners threw cold water on the ADAURA fervor. Sure, the disease-free survival data look good, but overall survival is the endpoint that matters when it comes to choosing adjuvant therapy for non-small cell lung cancer patients, the experts said.

The OS data still aren’t here, but AstraZeneca is back at ESMO to bolster their case with a look at brain metastasis data.

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

Rep. Andy Harris (R-MD) (Tasos Katopodis/Pool via AP Images)

UP­DAT­ED: A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

A small biotech that has talked up a potentially promising but unproven treatment for Covid-19 enlisted an unusual member for its study’s Data and Safety Monitoring Board: a sitting Republican congressman with close ties to the CEO and a history of mask skepticism.

NeuroRx, an Israeli biotech testing a lung inflammation drug in Covid-19 patients, tapped Maryland Rep. Andy Harris for the DSMB, Politico reported. Harris is an anesthesiologist but not a biostatistician, and he has questioned the CDC about a “cult of masks” in the US. Harris has known NeuroRx CEO Jonathan Javitt since the two worked at Johns Hopkins together over 20 years ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Everyone in the cancer R&D arena is looking to build new franchises around better drugs and combos. And one busy pocket of that space is centered entirely on creating an IL-2 drug that can be as effective as the original without the toxicity that damned it to the sidelines.

Alkermes $ALKS formally tossed its hat into the ring of contenders at virtual ESMO today, highlighting the first glimpse of efficacy for their candidate, ALKS 4230, as both a monotherapy as well as in combination with Merck’s Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

Yesterday, after sustained public pressure as Moderna released its Phase III Covid-19 trial blueprint, Pfizer released its own full trial design for their vaccine trials. The move was designed to boost transparency and shore up public trust in the vaccines, but it also revealed differences in how the two companies are approaching the much-watched studies while failing to satisfy the demands of the fiercest advocates for transparency.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Stronger to­geth­er? Boehringer and Mi­rati team to put first KRAS-KRAS com­bo in the clin­ic

Researchers are still waiting to see how much any of the vaunted KRAS drugs now in the clinic can, after decades of preclinical research and some early human studies, help patients. But while they do, two of the leading developers will look to see whether a KRAS-KRAS combo might pose a better shot than any KRAS alone.

Boehringer Ingelheim and Mirati have signed a collaboration to combine Mirati’s closely-watched lead KRAS inhibitor, MRTX849, in a clinical trial with the pan-KRAS blocker that Boehringer has quietly developed with high expectations behind their flashier contenders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.